BMY

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Bristol-Myers Squibb Co.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
CEO
Giovanni Caforio
Employees
30250
Headquarters

430 E 29th St Fl 14
New York, New York 10016-8367
Phone: 12125464000
www.bms.com

News

Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Jun 12, 2024 06:04am

https://www.investing.com/news/press-releases/evotec-announces-progress-in-neuroscience-collaboration-with-bristol-myers-squibb-93CH-3480568


Source:Investing.com
Evotec & Bristol Myers Squibb Make Breakthrough in Neuroscience Collaboration
Jun 12, 2024 05:35am

Evotec and Bristol Myers Squibb make strides in their neuroscience partnership, with a significant scientific milestone unlocking a $20 million research payment. Their joint efforts target breakthrough treatments for neurodegenerative diseases. Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
Jun 12, 2024 05:30am

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb 12.06.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis)
Jun 11, 2024 20:05pm

No summary available.


Source:Seeking Alpha
Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthcare Conference
Jun 11, 2024 18:35pm

No summary available.


Source:Seeking Alpha
Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer
Jun 09, 2024 23:25pm

The FDA has approved Geron Corporation’s drug, imetelstat, for the treatment of anemia in adults with low- to intermediate-risk myelodysplastic syndromes. This marks the company’s first commercialized product and provides competition against Bristol Myers Squibb’s blockbuster drug. The approval is based on the drug’s ability to enable bone marrow recovery and normal red blood cell…


Source:Dataemia
Bristol Myers: Quality Fundamentals Suppressed By Interest Rates
Jun 09, 2024 07:34am

No summary available.


Source:Seeking Alpha
Bristol Myers Squibb wins antitrust case against insurers regarding generics
Jun 08, 2024 14:19pm

New Jersey federal court rules in favor of Bristol Myers Squibb in a case brought by health insurers alleging anti-competitive practices for cancer drugs. Read more here.


Source:Seeking Alpha
Smart Money Is Betting Big In BMY Options
Jun 07, 2024 20:46pm

Investors with a lot of money to spend have taken a bullish stance on Bristol-Myers Squibb (NYSE: BMY ). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don''t know. But when something this big happens with BMY, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga ''s options scanner spotted 8 uncommon options trades for Bristol-Myers Squibb. This isn''t normal. The overall sentiment of these big-money traders is split between 75% bullish and 25%, bearish. Out of all of the special options we uncovered, 3 are puts, for a total amount of … Full story available on Benzinga.com


Source:Benzinga
Here’s Why Jim Cramer Says You Should Not Buy Bristol-Myers Squibb Co (NYSE:BMY)
Jun 05, 2024 13:49pm

We recently published the list of 11 stocks Jim Cramer is bearish on. Bristol-Myers Squibb Co (NYSE:BMY) ranks 2nd in the list. Click to see the full list of 11 stocks Cramer is bearish on. In this article we will take a deeper look at BMY and find out whether Cramer’s thesis holds any weight. […]


Source:Insider Monkey